Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 420Lymphoma 53Recurrence 42Neoplasms, Plasma Cell 33Hematologic Neoplasms 33Immunoglobulin Light-chain Amyloidosis 29Smoldering Multiple Myeloma 26Lymphoma, Non-Hodgkin 25Leukemia, Myeloid, Acute 20Leukemia, Lymphocytic, Chronic, B-Cell 20Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Hodgkin Disease 17Myelodysplastic Syndromes 16Monoclonal Gammopathy of Undetermined Significance 13Waldenstrom Macroglobulinemia 11Lymphoma, Mantle-Cell 11Leukemia 11Prostatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Breast Neoplasms 10Paraproteinemias 9Ovarian Neoplasms 9Lung Neoplasms 8Leukemia, Plasma Cell 8Amyloidosis 8Melanoma 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7

Interventions

pomalidomide 1daratumumab 1Immunotherapy, Adoptive 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Plasmacytoma × Plasma cell × 90 days × Clear all
NCT01946477 2026-05-22

POM MM 014

Celgene

Phase 2 Completed
186 enrolled 17 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT06429150 2026-04-24

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Shenzhen Geno-Immune Medical Institute

Phase 1/2 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT06435910 2026-04-24

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Shenzhen Geno-Immune Medical Institute

Phase 1 Recruiting
10 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡